Last reviewed · How we verify
JNJ-55375515 Dose Level 4 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
JNJ-55375515 Dose Level 4 (JNJ-55375515 Dose Level 4) — Janssen Research & Development, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JNJ-55375515 Dose Level 4 TARGET | JNJ-55375515 Dose Level 4 | Janssen Research & Development, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JNJ-55375515 Dose Level 4 CI watch — RSS
- JNJ-55375515 Dose Level 4 CI watch — Atom
- JNJ-55375515 Dose Level 4 CI watch — JSON
- JNJ-55375515 Dose Level 4 alone — RSS
Cite this brief
Drug Landscape (2026). JNJ-55375515 Dose Level 4 — Competitive Intelligence Brief. https://druglandscape.com/ci/jnj-55375515-dose-level-4. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab